CrisprBits and Molbio Diagnostics to jointly launch innovative CRISPR-based PoC tests
INDIA – CrisprBits and Molbio Diagnostics have agreed to jointly unveil innovative CRISPR-based Point-of-Care (POC) tests, marking a significant step forward in the revolution of point-of-care diagnostics.
Under the new agreement with Molbio Diagnostics, CrisprBits will spearhead the development of its platform, PathCrisp, for Point-of-Care testing (POCT).
The two companies will not only develop instrument-light CRISPR POCTs but also distribute a new generation of tests that are pervasive and will enable early detection and timely treatment.
This collaboration will focus on building Point-of-Care tests for swift and accurate detection of various pathogens and genetic markers at the site.
Commenting on this partnership with CrisprBits, Dr. Chandrashekar Nair, Chief Technical Officer of Molbio Diagnostics, said: “The coming together of their innovation and Molbio’s strengths in translation, manufacturing, and distribution has the potential to rapidly provide cutting edge diagnostics solutions where it is required the most.”
Point-of-care testing is diagnostic testing conducted at the site of patient care that provides quick results allowing physicians to make a rapid diagnosis and immediate treatment.
CrisprBits has developed an innovative platform that has scientific capabilities to build rapid, precise, and affordable Point-of-Care tests for a wide range of diseases and health conditions.
As a result, CrisprBits and Molbio Diagnostics are set to empower health professionals with innovative PoC tests, enabling them to deliver better preventive care, early detection interventions, and effective treatment of diseases.
The duo plans to deploy the CRISPR-based PoC tests in low- and middle-income countries (LMICs) as well as developed economies.
The PoC tests will be made available in diverse settings, including clinics, hospitals, and resource-limited areas, where access to reliable diagnostic tools is crucial.
Laying out his aspirations, Dr. Chandrashekar Nair, stated: “This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally.”
Hence, this collaboration builds on pooled efforts to address the lack of accessibility of healthcare infrastructure in LMICs while empowering people to benefit from the full range of diagnostic testing services.
Commenting on this joint effort, Dr. Vijay Chandru, Chief Scientific Officer and Co-founder of CrisprBits, said: “The reimagination of health systems in India has to ride on a central role played by advanced PoC tests that are light on instruments, affordable and designed for ease of use by community health workers.”
The strategic partnership between CrisprBits and Molbio Diagnostics represents a significant milestone in the advancement of accessible, cost-effective, and accurate diagnostic testing in frontline care delivery.
Through this collaboration, the duo intends to leverage their respective strengths and expertise to identify and capitalize on market opportunities in the diagnostic industry.
The strategic alliance aims to streamline the development, manufacturing, and distribution processes, ensuring the swift availability of CRISPR-based PoC tests to healthcare facilities and communities around the world.
On this account, Molbio Diagnostics will leverage its large-scale manufacturing capability and well-established sales and marketing network to promote and distribute the developed POC tests worldwide.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment